Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Inclusion Criteria Exclusion Criteria Timeline for a Trial Participant Screening Participants are screened for eligibility to participate in the trial Treatment Participants receive once-weekly subcutaneous injections of CagriSema or placebo for up to 40 weeks, with dose escalation periods for active comparators Follow-up Participants are monitored for safety and effectiveness after treatment What Are the Treatments Tested in This Trial
Healthcare is tough these days so thank you for still being so kind
(Amsterdam: Elsevier B.V.), 157171
Obstructive sleep apnea and psychiatric disorders: a systematic review
Both are once-weekly amylin receptor agonists, but eloralintide is selective for the amylin receptor while cagrilintide also activates the calcitonin receptor, making it a dual amylin and calcitonin receptor agonist
